FY03/16 Financial Results Briefing



ココロ、カラダ、ゲンキ。



FY03/16 Business Results

Earnings Highlights

Consolidated Income Statement (vs. Forecasts

Revised Feb. 26)

Consolidated Income Statement (YoY)

Monthly Sales Growth Rate

Loyal Customer trends owing to Customer

Strategy

Breakdown of Sales by Product Category

Factors impacting income (YoY / Ordinary Income

Basis)

Consolidated Balance Sheet

Consolidated Cash Flow Statement

FY03/17 Outlook

13

3

Store Openings and Closings(Actual and Planned) Consolidated Forecasts

Management Strategy

- FY03/17 Key Measures
 - Drugstore Operations
 - Stimulating demand at existing stores
 - Increasing efficiencies
 - Pharmacy Operations
 - Effects and Countermeasures to Medical Service Fee Revision
 - Promotion of "Health Support Pharmacy" and Business Plan

Medium-term Plan

Medium-term Plan

Consolidated Sales & Ordinary Income (Trends and Plan)

(Reference) Inbound tourist demand · Private Brand products



FY03/16 Business Results

Earnings Highlights

Earnings solid as progress was made in implementing key measures, earnings forecasts revised upward on Aug and Feb.

- [Drugstore Operations]
- [Key measures]

1 Net sales get boost from revitalization measures, driven mainly by the renovation of 79 stores
 2 Promotion of sales to inbound tourists

③Progress in improving cost efficiencies, expense ratio reduced

[Others]

- Net sales get boost from summer products and new product introductions (1H)
- Drop in FY03/14 sales following the consumption tax hike, so FY03/15 sales were up YoY (1H)
- Net sales pushed downward due to weak performance in cold-related medications owing to a warm winter (2H)

[Pharmacy Operations]

Pharmacy Operations saw continued solid performance, with contribution from the new hepatitis C medication boosting sales

[Nursing Care Services]

 Although profitability was steady for nursing house call services and composite facilities for functional training rehabilitation, both of which serve as an outlet for residential medical care, the effects of revisions to nursing service fees could not be offset

[Store Openings and Closings]

•Opened 19 stores and closed 53 stores, for a total store count of 1,307 (including 232 dispensing pharmacies)

Consolidated Income Statement (vs. Forecasts Revised Feb. 26)

こ こっカラファイン

(Million yen)

5

| | FY03/16 FY03/16 Plan Results | | vs Plan | vs Plan (%) | Factors | | | | | | | | | |
|-----------------|---------------------------------|----------------------------|-------------------------|------------------|---------|---|--|------------|--|------------|--|------------|--|---|
| | Net sales | 370,000 (100.0%) | 373,275 (100.0%) | +3,275 | 100.9 | ♦ Same-store sales growth Plan +6.6% → Result +7.4% ♦ Sales growth due to rapid change in | | | | | | | | |
| | Drugstore & Dispensing | 336,557 | 339,646 | +3,089 | 100.9 | temperatures February: Growth in cold and allergy-related products | | | | | | | | |
| | Wholesale & other | 33,443 | 33,629 | 33,629 +186 100. | | +186 100.6 | | +186 100.6 | | +186 100.6 | | +186 100.6 | | March: Growth in summer products Increase in inbound tourists from overseas for cherry blossom viewing |
| | Gross profit | 95,250 (25.7%) | 96,068 (25.7%) | +818 | 100.9 | | | | | | | | | |
| | SG&A | 84,750 (22.9%) | 84,949 (22.8%) | +199 | 100.2 | SG&A:+199 Effects of renovation investment, advance ICT investment, etc. | | | | | | | | |
| Op | erating income | 10,500 (2.8%) | 11,119 (3.0%) | +619 | 105.9 | | | | | | | | | |
| Ordinary income | | 13,000 (3.5%) | 13,461 (3.6%) | +461 | 103.5 | | | | | | | | | |
| Net income | | 6,500 (1.8%) | 6,927 (1.9%) | +427 | 106.6 | | | | | | | | | |


Consolidated Income Statement (YoY)

こ ココカラファイン

(Million yen)

| | | FY03/15 Results | FY03/16 Results | Change | YoY (%) | Factors influencing YoY changes |
|----------------------------|---------------------------|------------------------|----------------------------|---------|---|--|
| | Net sales | 349,164 (100%) | 373,275 (100.0%) | +24,111 | 106.9 | Same-store sales growth: +7.4% Revitalization policy centered on existing store renovation Sales promotion to inbound tourists |
| | Drugstore & Dispensing | 317,969 | 339,646 | +21,677 | 106.8 | Impact of consumption tax in FY03/14 Dispensing sales strong, contribution from new hepatitis C medication Change of Iwasakikohkendo's fiscal year |
| | Wholesale & other | 31,195 | 33,629 | +2,434 | 107.8 | end (from Feb. to Mar.) meant an additional month of its sales booked at the parent ♦ New store openings:19 Closings:53 |
| (| Gross profit | 88,778 (25.4%) | 96,068 (25.7%) | +7,290 | 108.2 | Gross margin: from 25.4% to 25.7% Strong sales of value-added products Standardization of product line-up and prices |
| | SG&A | 84,408 (24.2%) | 84,949 (22.8%) | +541 | 100.6 | \$\$SG&A:+541 Change of Iwasakikohkendo's fiscal year end from Feb. to Mar. meant an additional month of its costs booked at the parent \$\$SG&A ratio:from 24.2% to 22.8% Improved efficiency in back-office divisions |
| Оре | erating income | 4,369 (1.3%) | 11,119 (3.0%) | +6,750 | 254.4 | ※ Record high income |
| Ord | dinary income | 6,576 (1.9%) | 13,461 (3.6%) | +6,885 | 204.7 | |
| Net income 1,658 (0.5%) | | 6,927 (1.9%) | +5,269 | 417.7 | ♦ Extraordinary Losses : ▲781 Lower loss on valuation of shares of subsidiaries and associates ♦ Corporate tax rate : from 61.0% to 40.8% | |

Monthly Sales Growth Rate




7

- ココカラファイ

こ コンカラファイン

Sales composition of retail sales (trend)



Breakdown of Sales by Product Category

こ ココカラファイン

| | F | Y03/15 | | FY03/16 | | | | |
|----------------------------|-------------|-----------|---------|--------------|-----------|---------|--|--|
| | Million yen | Share (%) | YoY (%) | Millions yen | Share (%) | YoY (%) | | |
| Pharmaceuticals | 100,555 | 31.6 | 101.3 | 105,975 | 31.2 | 105.4 | | |
| Dispensing | 45,967 | 14.4 | 103.9 | 50,228 | 14.8 | 109.3 | | |
| Beauty Products | 91,492 | 28.8 | 96.0 | 99,286 | 29.2 | 108.5 | | |
| Health Foods | 10,262 | 3.2 | 101.9 | 11,431 | 3.4 | 111.4 | | |
| Sanitary Goods | 39,941 | 12.6 | 99.7 | 42,329 | 12.5 | 106.0 | | |
| Convenience Goods | 44,786 | 14.1 | 99.8 | 46,329 | 13.6 | 103.4 | | |
| Foods | 30,931 | 9.7 | 108.3 | 34,294 | 10.1 | 110.9 | | |
| Stores Total | 317,969 | 100.0 | 99.9 | 339,646 | 100.0 | 106.8 | | |
| Wholesale | 28,993 | - | 98.8 | 31,388 | - | 108.3 | | |
| Subtotal | 346,962 | _ | 99.9 | 371,034 | _ | 106.9 | | |
| Long-term Care | 2,202 | _ | 116.2 | 2,243 | - | 101.9 | | |
| Inter-segment Eliminations | ▲0 | _ | _ | ▲2 | _ | - | | |
| Total | 349,164 | _ | 99.9 | 373,275 | _ | 106.9 | | |

(Pharmaceuticals)

Robust sales of hay fever related products and high value-added eye drops and lotions

(Dispensing)

(Beauty Products) Robust sales of new products


(Health Foods) Favorable owing to hit products such as smoothies, etc.

(Foods) Strengthened functions via store renovations and layout changes, etc.

New hepatitis C medication contributed to earnings

Factors impacting income (YoY / Ordinary Income Basis)

コンカラファイン



Consolidated Balance Sheet

こ ココカラファイン

End Mar. 2015

5 🛛 End Mar. 2016



Comparison with end March 2015

(Million yen)

| Current Assets | +8,417 | Non-current assets | ▲ 1,623 | Liabilities | +4,074 |
|--------------------------|--------|-------------------------------|----------------|----------------------------|--------|
| Cash and Equivalents | +6,738 | Property, plant and equipment | +149 | Current liabilities | +3,444 |
| Accounts receivabletrade | +2,889 | Intangible fixed assets | ▲445 | Non-current liabilities | +630 |
| Inventories | ▲1,116 | Investments and other assets | ▲1,327 | | |

| ,074 | Net assets | +2,719 |
|------|----------------------|--------|
| ,444 | Treasury stock | ▲2,601 |
| -630 | Retained earnings | +5,438 |


Consolidated Cash Flow Statement

こ ココカラファイン

(Million yen)

FY03/15 FY

FY03/16



Situation in FY03/16

| Cash flows from o activities | perating | Cash flows from inve- activities | sting | Cash flows from financial activities | | |
|---|----------|---|--------|--|---------|--|
| Income before income taxes and minority | 11,705 | Purchase of property, plant and equipment | ▲3,306 | Increase (decrease) in short-term borrowings | ▲3,000 | |
| interests Decrease (increase) in notes and accounts receivable-trade | ▲2,889 | Purchase of intangible fixed assets | ▲371 | Purchase of treasury stock | ▲2,601 | |
| Decrease (increase) in inventories | 1,115 | | | Net increase (decre cash and cash equi | valents | |
| Income taxes paid | ▲1,684 | | | | 6,738 | |



FY03/17 Outlook

Store Openings and Closings (Actual and Planned)

こ ココカラファイン

| | Designing | | | FY03/16 Results | | | | FY03/17 Full-year Plan | | | |
|------|-------------------------|------------------------|------|-----------------|---------------------------|---------------|------|------------------------|---------------------------|---------------|--|
| | | Beginning of period | Open | Close | Store format change | End of period | Open | Close | Store format change | End of period | |
| coco | cocokara fine | | +19 | ▲53 | - | 1,307 | +29 | ▲28 | - | 1,308 | |
| Ba | Bases that dispense | | +4 | ▲6 | - | 232 | +8 | - | - | 240 | |
| СС | ocokarafine Healthcare | 1,283 | +19 | ▲53 | - | 1,249 | +27 | ▲28 | - | 1,248 | |
| | Drugstore | 1,161 | +16 | ▲51 | ▲6 | 1,120 | +21 | ▲28 | - | 1,113 | |
| | Standalone dispensaries | 122 | +3 | ▲2 | +6 | 129 | +6 | - | - | 135 | |
| IV | IWASAKI KOHKENDO | | - | - | - | 58 | +2 | - | - | 60 | |

| | FY03/16 Results | FY03/17 Full-year Plan |
|--------------------------|-----------------|------------------------|
| Capital investment | 5,776 | 6,800 |
| Total cash flow | 10,830 | 12,553 |
| Net income | 6,927 | 8,500 |
| Depreciation | 3,518 | 3,769 |
| Amortization of goodwill | 385 | 284 |



| | 2H (AprSep.) | | | | | | Full-Year | | | | | |
|---------------------------|--------------|----------------|-------------|----------------|------------|--|-------------|----------------|-------------|----------------|------------|--|
| | FY03/1 | 6 | FYC |)3/17 | | | FY03/1 | 6 | FY03/17 | | | |
| | Result | S | For | ecast | | | Result | S | For | ecast | | |
| | Million yen | % of net sales | Million yen | % of net sales | YoY (%) | | Million yen | % of net sales | Million yen | % of net sales | YoY (%) | |
| Net sales | 186,798 | 100.0 | 193,000 | 100.0 | 103.3 | | 373,275 | 100.0 | 386,000 | 100.0 | 103.4 | |
| Drugstore & Dispensing | 170,154 | 91.1 | 175,300 | 90.8 | 103.0 | | 339,646 | 91.0 | 350,800 | 90.9 | 103.3 | |
| Wholesale & other | 16,644 | 8.9 | 17,700 | 9.2 | 106.3 | | 33,629 | 9.0 | 35,200 | 9.1 | 104.7 | |
| Gross profit | 47,949 | 25.7 | 49,630 | 25.7 | 103.5 | | 96,068 | 25.7 | 99,500 | 25.8 | 103.6 | |
| SG&A | 42,587 | 22.8 | 43,560 | 22.6 | 102.3 | | 84,949 | 22.8 | 86,900 | 22.5 | 102.3 | |
| Operating income | 5,362 | 2.9 | 6,070 | 3.1 | 113.2 | | 11,119 | 3.0 | 12,600 | 3.3 | 113.3 | |
| Ordinary income | 6,570 | 3.5 | 7,190 | 3.7 | 109.4 | | 13,461 | 3.6 | 14,800 | 3.8 | 109.9 | |
| Net income | 3,790 | 2.0 | 4,200 | 2.2 | 110.8 | | 6,927 | 1.9 | 8,500 | 2.2 | 122.7 | |



Management Strategy



FY03/17 Key Measures




Drugstore Operations

- Stimulating demand at existing stores
 - creating new customers through use of digital platforms and improving satisfaction of existing customers
 - revitalization of existing stores through renovations
- Increasing efficiencies
 - improving efficiency of store operations by utilizing the latest mobile devices

Pharmacy Operations

- Effects and Countermeasures to Medical Service Fee Revision
- Promotion of "Health Support Pharmacy" and Business Plan

Creating new customers through use of digital platforms and improving satisfaction of existing customers



こ ココカラファイン

Invigorating existing stores through renovations

Horizontally expand prototype stores by cluster

Urban drugstores <u>/154stores</u>

Expand range of beauty care products, creating sales floors incorporating trends



Drugstores in shopping streets / 331sores

Expanding storefront promotions, strengthening promotion of seasonal products



Drugstores in residential areas / 423stores

Product line-up that satisfies uses and functions, including expanding home care products and foods



Community drugstores / 212 stores

Product line-up that allows onestop shopping, including foods




(as of Mar. 31,2016)

Accelerating store renovations




こ ココカラファイン

improving efficiency of store operations by utilizing the latest mobile devices





Effects and Countermeasures to Medical Service Fee Revision





Promote pharmacies that support health


By mainly **fostering "family pharmacies,"** continue to streamline and optimize operations

| 1) | Enriching self-health management functions via implementation of health monitoring stations and health consultation meetings, etc., including advice on self-medication and improving overall quality of life | | | | | | | | | |
|------|---|-----------------------------|------|-------------------|---|-------------------------------------|--------------|-------|------------------------------|--|
| 2) | - | on of house peration wit | | | | House call disp FY03/16 1 | | | FY03/17 (Plan) 200 stores | |
| 3) |) Fostering specialized pharmacists and dedicated staff that can support dementia, diabetes, and cancer patients | | | | | | | | | |
| 4) | | ing product ing pharmad | | ctions in | | FY03/16 Pro 123% | | | FY03/17 (Plan) 130% YoY | |
| Busi | iness P | lan | | | | | | | | |
| | | FY03/16 | F | Y03/17(Plan) | | | FY03/ | 16 | FY03/17(Plan) | |
| • | ensing ees | JPY 50.2 | bn J | PY 50.3 bn | | otal number of facilities | 232 s | tores | 240 _{stores} | |
| | | | | | 7 | | | | | |




Medium-term Plan

Medium-term plan through FY03/20.




Consolidated Sales & Ordinary Income (Trends and Plan)



ココカラファイン

こ ココカラファイン

Responding to inbound tourist demand





Private Brand Strategy

PB composition growth stalled due to effects of inbound tourists and weak sales of cold medicines owing to warm winter, etc.





DEARPERFECT

FY03/16: Hit product selling more than 80,000 units

Surfactant-free sunscreen that utilizes patented technology from Kanagawa University(JPY1,850/ex. tax New products introduced in Mar.2015)



Cocokara Fine Inc.

http://www.cocokarafine.co.jp/english/

The information published on this book is intended to provide financial data and management indicators on cocokara fine Inc. and its affiliates (hereinafter, "the Company"). Nevertheless, the Company does not make any warranties or statements regarding the content of this information.

Some of the information appearing on this book contains mention of the future performance of the Company. These forward-looking statements do not guarantee future performance and include risk and uncertainties. The actual performance of the Company may differ from such statements due to changes in the business environment or other factors.